NCT01972347View on ClinicalTrials.gov

Neoadjuvant Dabrafenib + Trametinib for AJCC Stage IIIB-C BRAF V600 Mutation Positive Melanoma

PHASE2Active, not recruitingINTERVENTIONAL
Enrollment

35

Participants

Timeline

Start Date

October 1, 2014

Primary Completion Date

May 4, 2017

Study Completion Date

May 1, 2026

Conditions
Melanoma
Interventions
DRUG

Dabrafenib

Patients will receive neoadjuvant treatment with dabrafenib 150mg twice a day and trametinib 2mg once a day for 12 weeks. Patients will then have complete lymph node dissection and will continue on maintenance treatment with dabrafenib 150mg twice a day and trametinib 2mg once a day for 40 weeks.

DRUG

Trametinib

Patients will receive neoadjuvant treatment with dabrafenib 150mg twice a day and trametinib 2mg once a day for 12 weeks. Patients will then have complete lymph node dissection and will continue on maintainance treatment with dabrafenib 150mg twice a day and trametinib 2mg once a day for 40 weeks.

Trial Locations (1)

2060

Melanoma Institute Australia, North Sydney

All Listed Sponsors
lead

Melanoma Institute Australia

OTHER